Discounted stock prices make these strong brands worth considering as investments. Let's take a look at two stocks that trade down significantly from recent highs and see why they might be good stocks to buy right now. Smart investors see that disparity and know it means there are some discounted stocks to be found. The trick, of course, is discerning which of the discounted stocks represent quality companies experiencing a short-term issue (or issues). Not every stock that falls is a wise investment. Howev ...

Group 1: Healthcare Sector Outlook - The outlook for many healthcare stocks is positive, partly due to large investors avoiding the sector, believing it will yield poor returns as long as interest rates remain high [1] Group 2: Walgreens Boots Alliance (WBA) - Walgreens is facing tough competition from large retail chains like Walmart and Target, and increased use of direct mail prescription services has negatively impacted its earnings, which fell to 63 cents per share from 99 cents year-over-year [3] - Analysts predict Walgreens' earnings per share will decline to $2.79 in 2025 from $3.98 in 2023 [4] - The company has significant challenges, including high settlements related to the opioid crisis, resulting in a debt of $33.66 billion and only $711 million in cash as of the end of Q1 [10] - Increased shoplifting and inflation have further hurt Walgreens' financial results, making consumers less willing to pay high prices compared to competitors [19] Group 3: Cassava Sciences (SAVA) - Cassava's only major drug candidate, simufilam, is under scrutiny after Professor Hoau-Yan Wang was indicted for allegedly falsifying data, which could jeopardize the drug's Phase 3 trials [5][11] - If the FDA finds that Cassava knowingly submitted false data, it could lead to severe consequences for the company and a significant drop in its stock price [6][11] - Cassava has been accused of manipulating clinical trial results, raising concerns about the drug's efficacy [12][22] Group 4: Moderna (MRNA) - Moderna's revenue from its Covid-19 vaccine dropped significantly by two-thirds to $6.7 billion last year, as public concern about the virus decreased [14] - Analysts expect Moderna's revenue to decline to $3.85 billion this year from $6.85 billion in 2023 [15] - Moderna's RSV vaccine efficacy is reported at 50% after 18 months, which is less impressive compared to GSK's vaccine that was approved earlier [24]

Core Insights - Moderna announced a $176 million federal grant to develop a bird flu vaccine for humans, focusing on the H5 influenza virus which poses a significant risk to both birds and humans [1][2] - The grant is part of the Rapid Response Partnership Vehicle (RRPV) from the U.S. Department of Health and Human Services, aimed at accelerating mRNA-based vaccine development [2] - Moderna has initiated a Phase 1/2 trial for the H5 influenza vaccine in 2023, with results expected this year to inform further development plans [3][6] Financial Impact - Following the announcement of the federal grant, Moderna's shares increased by 0.5% to $116.54, marking a 17% rise in share value so far in 2024 [4][7] Public Health Context - The CDC reported four human cases of bird flu since 2022, with the WHO documenting 254 cases globally since January 2023, highlighting the ongoing public health concern [5]

Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans . Getty Images Moderna said the U.S. government funds will bankroll "late-stage development for an mRNA-based vaccine" against H5 influenza virus to en ...

The CHMP's recommendation will now be reviewed by the European Commission (EC) and a final decision is expected shortly. If authorized, mResvia will be Moderna's second approved product in the region. The above news comes just a few days after Moderna suffered a major setback after the U.S. Centers for Disease Control and Prevention (CDC) revised their recommendation for the use of RSV vaccines for the upcoming respiratory virus season. This recommendation is based on data from data from the phase III Conqu ...

Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials. Undoubtedly, most of the drug candidates will run into a wall at some point in the trials. It can be a long and grueling move from Phase I to the finish line. For the biotech firms that can advance past all clinical trials and prove that a treatment is both safe and effective, the rewards could have the po ...

An 18-month analysis of follow-up data showed that Moderna's RSV vaccine was just about 49.9% effective in preventing RSV-LRTD. This is significantly lower compared with the 80.9% vaccine efficacy achieved by the vaccine at a follow-up period of 3.7 months. Image Source: Zacks Investment Research This efficacy rate was also significantly lower compared with GSK's Arexvy and Pfizer's Abrysvo, both of which are also approved for similar use by the FDA. These companies also presented data on their respective R ...

The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks that have dropped in the double digits over the past few years are coronavirus vaccine giants Moderna (MRNA -11.01%) and Pfizer (PFE -2.04%). Adria Cimino (Moderna): Moderna entered the coronavirus vaccine market with a splash in early pandemic days, becoming a vaccine leader along with Pfizer. The vaccine, Moderna' ...

Loading... In the presentation slides to the U.S. agency, Moderna Inc MRNA shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms. Efficacy of a single dose of GSK Plc's GSK Arexvy over two calendar years showed vaccine efficacy of 73.3% (W/o season covariate) and 78.6% in severe infection. Last year, GSK's Arexvy and Pfizer's Abrysv ...

Moderna Today Moderna -5.20 (-3.58%) ▼ Price Target $129.02 Biotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments. The company continues expanding its treatments for various diseases and illnesses, including cardiovascular disease, cancer, and other rare diseases. Moderna has been working on personalized cancer vaccines that will enable a cancer p ...